NCT00311545撤回2 期
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well CNTO 328 works in treating patients with unresectable or metastatic kidney cancer.
详细描述
OBJECTIVES:
Primary
- Assess the probability of response (confirmed complete and partial responses) in patients with unresectable or metastatic renal cell cancer treated with CNTO 328.
Secondary
- Assess the 6-month progression-free survival probability and median overall survival in these patients.
- Evaluate the qualitative and quantitative toxicities of this treatment.
- Investigate, in a preliminary manner, the association of tumor response with potential markers of anti-interleukin-6 activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed metastatic or unresectable primary renal cell carcinoma
- •Measurable disease
- •Soft tissue disease within a prior radiation field may be considered measurable disease provided all of the following are true:
- •Patient also has measurable disease outside of the irradiated field
- •Disease within the irradiated field has progressed since prior radiotherapy
- •Radiotherapy was completed more than 2 months ago
- •Ineligible for high-dose interleukin-2
- •No treated or untreated brain metastases
- •No history of brain metastases
- •Patients with clinical evidence of brain metastases must have brain CT scan or MRI negative for metastatic disease within 56 days prior to study entry
- •PATIENT CHARACTERISTICS:
- •Zubrod performance status 0-2
- •Absolute granulocyte count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Creatinine clearance ≥ 40 mL/min
- •Bilirubin ≤ 3 times upper limit of normal (ULN)
- •SGOT ≤ 3 times ULN
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No more than 2 of the following:
- •Zubrod PS 2
- •Lactate dehydrogenase > 1.5 times ULN
- •Hemoglobin < lower limit of normal
- •Calcium > 10 mg/dL
- •Absence of prior nephrectomy
- •No uncontrolled intercurrent illness, including any of the following:
- •Uncontrolled diabetes mellitus
- •Ongoing or active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •Cardiac arrhythmia
- •Psychiatric illness or social situation that would limit compliance with study requirements
- •No HIV positivity
- •No other prior malignancy, excluding the following:
- •Adequately treated basal cell or squamous cell skin cancer
- •In situ cervical cancer
- •Adequately treated stage I or II cancer for which the patient is currently in complete remission
- •Any other cancer for which the patient has been disease free for 5 years
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •At least 28 days since prior tumor resection and recovered
- •No prior immunotherapy or chemotherapy regimens with interferon (IFN) and/or interleukin-2 (IL-2) or the combination of IFN/IL-2
- •No prior cytotoxic chemotherapy for renal cell cancer
- •No prior murine or chimeric proteins or human/murine recombination products (i.e., other chimeric monoclonal antibodies)
- •No concurrent radiotherapy or systemic therapy for renal cell cancer
排除标准
- 未提供
研究组 & 干预措施
CNTO 328
Experimental
CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
干预措施: CNTO 328 (Biological)
研究者
相似试验
已完成
2 期
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyProstate CancerNCT00433446SWOG Cancer Research Network62
终止
2 期
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube CancerPeritoneal Cavity CancerFallopian Tube CancerOvarian CancerNCT01137071Recepta Biopharma29
已完成
2 期
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by SurgeryPancreatic CancerNCT00601627Alliance for Clinical Trials in Oncology52
终止
2 期
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By SurgeryBreast CancerNCT00674414UNICANCER82
已完成
2 期
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00556413Institut du Cancer de Montpellier - Val d'Aurelle42